Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Hyun‐Ae Jung"'
Autor:
Jiyun Lee, Jiae Koh, Hee Kyung Kim, Sungsoo Hong, Kyunga Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Publikováno v:
Journal of Thoracic Oncology. 17:900-908
Vascular endothelial growth factor promotes an immunosuppressive tumor microenvironment that can be reverted by an antiangiogenic therapy. This two-stage, phase 2 study aimed to determine the treatment efficacy of adding bevacizumab to atezolizumab i
Autor:
Kyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, Dongryul Oh, Jae Myoung Noh, Yong Chan Ahn, Hong In Yoon, Hyowon Moon, Jiyun Lee, Sehhoon Park, Hyun-Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Bo Mi Ku, Myung-Ju Ahn, Eui-Cheol Shin
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 113:415-425
Chemoradiotherapy (CRT) followed by consolidation immune checkpoint inhibitors significantly improves survival in unresectable locally advanced non-small cell lung cancer. However, the optimal sequence for CRT and immune checkpoint inhibitors has not
Autor:
Sehhoon Park, Jin Seok Ahn, Jong-Mu Sun, Myung-Ju Ahn, Hyun Ae Jung, Keunchil Park, Hongsik Kim, Se-Hoon Lee
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Metachronous brain-only oligorecurrence in patients with non–small cell lung cancer (NSCLC) is a rare event with favorable prognosis, but the clinical outcome has not been fully determined. We retrospectively analyzed clinical outcomes and
Autor:
Angela Märten, Min Ki Lee, C. Escriu, Nicolas Girard, H. Daoud, Shin Yup Lee, Sanjay Popat, Maximilian Hochmair, Seung Hyeun Lee, Satoru Miura, Hyun Ae Jung, Yong Chul Lee, Maria Rita Migliorino
Publikováno v:
Lung Cancer. 162:9-15
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard of care for EGFR mutation-positive non-small cell lung cancer (NSCLC). However, optimal sequence of treatment has yet to be defined. Overall survival (O
Autor:
Hyun Ae Jung, Jong-Mu Sun, Cheol-In Kang, Jin Seok Ahn, Byeong-Ho Jeong, Sehhoon Park, Keunchil Park, Se-Hoon Lee, Yong-Pyo Lee, Myung-Ju Ahn, Yeonghee Eun
Publikováno v:
European Journal of Cancer. 159:167-173
Background Pralsetinib, an RET inhibitor, has shown a dramatic response in patients with RET fusion- or mutation-positive tumours in previous studies. As a novel target agent, however, the safety of pralsetinib remains to be determined. Herein, we pr
Autor:
Steve Olsen, Hyun-Ae Jung, Jin Seok Ahn, Myung-Ju Ahn, Se-Hoon Lee, Min-Sang Lee, Sehhoon Park, Yoon-La Choi, Jong-Mu Sun, Bo Mi Ku, Keunchil Park
Publikováno v:
Cancer. 127:3019-3028
Background Because of the growing number of actionable biomarkers in non-small cell lung cancer (NSCLC), sufficient tissue availability for testing is becoming a greater challenge. Liquid biopsy offers a potential solution by complementing standard t
Autor:
Hyun Ae Jung, Jinyeong Lim, Yoon-La Choi, Se-Hoon Lee, Je-Gun Joung, Yeong Jeong Jeon, Jae Won Choi, Sumin Shin, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi, Jae Ill Zo, Young Mog Shim, Sehhoon Park, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Joungho Han, Woong-Yang Park, Jhingook Kim, Keunchil Park
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(19)
Purpose: In early-stage, EGFR mutation–positive (EGFR-M+) non–small cell lung cancer (NSCLC), surgery remains the primary treatment, without personalized adjuvant treatments. We aimed to identify risk factors for recurrence-free survival (RFS) to
Autor:
Sehhoon Park, Chan-Young Ock, Hyojin Kim, Sergio Pereira, Seonwook Park, Minuk Ma, Sangjoon Choi, Seokhwi Kim, Seunghwan Shin, Brian Jaehong Aum, Kyunghyun Paeng, Donggeun Yoo, Hongui Cha, Sunyoung Park, Koung Jin Suh, Hyun Ae Jung, Se Hyun Kim, Yu Jung Kim, Jong-Mu Sun, Jin-Haeng Chung, Jin Seok Ahn, Myung-Ju Ahn, Jong Seok Lee, Keunchil Park, Sang Yong Song, Yung-Jue Bang, Yoon-La Choi, Tony S. Mok, Se-Hoon Lee
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(17)
PURPOSE Biomarkers on the basis of tumor-infiltrating lymphocytes (TIL) are potentially valuable in predicting the effectiveness of immune checkpoint inhibitors (ICI). However, clinical application remains challenging because of methodologic limitati
Autor:
Se-Hoon Lee, Hyun Ae Jung, Yong Chan Ahn, Hongryull Pyo, Jin Seok Ahn, Keunchil Park, Jong-Mu Sun, Myung-Ju Ahn, Jae Myoung Noh
Publikováno v:
Lung Cancer. 146:23-29
Objectives The PACIFIC study demonstrated the benefits of durvalumab consolidation on progression-free survival (PFS) and overall survival (OS) among patients with unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). However, in real-
Publikováno v:
Lung Cancer. 146:112-119
Introduction Until the recent approval of immunotherapy after completing concurrent chemoradiotherapy (CCRT), there has been little progress in treating unresectable stage III non-small cell lung cancer (NSCLC). This prompted us to search real-world